ABSTRACT
Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely administered antibiotic that is well tolerated by most patients. Hypersensitivity reactions and gastrointestinal intolerance are the most common adverse events associated with it. Central nervous system adverse effects such as tremors are less common and occur primarily in patients with acquired immune deficiency syndrome. A 29-year-old immunocompetent man developed a tremor while taking TMP-SMX. The tremor resolved within 2 days after the drug was discontinued.
Subject(s)
Anti-Infective Agents/adverse effects , Tremor/chemically induced , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Adult , Anti-Infective Agents/administration & dosage , Enterobacteriaceae Infections/drug therapy , Humans , Immunocompetence , Male , Postoperative Complications/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/administration & dosageSubject(s)
Contraception/methods , Contraceptives, Oral, Synthetic , Levonorgestrel/administration & dosage , Progesterone Congeners , Coitus , Contraceptives, Oral, Synthetic/administration & dosage , Emergencies , Female , Humans , Progesterone Congeners/administration & dosage , Tablets , United StatesABSTRACT
PIP: A study supported by the World Health Organization's Task Force on Postovulatory Methods of Fertility Control compared the efficacy of the Yuzpe and levonorgestrel-only methods of emergency contraception (EC). Enrolled in this double-blind, randomized trial were 1998 women from 21 centers around the world who requested EC within 72 hours of unprotected intercourse. The pregnancy rate was 1.1% for levonorgestrel alone and 3.2% for the combined ethinyl estradiol-levonorgestrel regimen. The crude relative risk of pregnancy was 0.36 (95% confidence interval, 0.18-0.70) for levonorgestrel compared with the Yuzpe regimen. The former method prevented 85% of expected pregnancies, while the latter prevented only 57%. Finally, side effects such as nausea, vomiting, dizziness, and fatigue were significantly less common in the levonorgestrel group. Although these findings document the superiority of the levonorgestrel regimen for EC, the 0.75 mg tablets are not currently manufactured in the US.^ieng
